MDNA vs. FRX, VBV, CUS, AIM, IPA, APM, GXE, CRDL, GPH, and CGC
Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include Fennec Pharmaceuticals (FRX), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), Cardiol Therapeutics (CRDL), Graphite One (GPH), and Canadian Gold (CGC). These companies are all part of the "pharmaceutical products" industry.
Medicenna Therapeutics vs. Its Competitors
Fennec Pharmaceuticals (TSE:FRX) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Fennec Pharmaceuticals has a beta of 2.091843, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 2.80428, meaning that its stock price is 180% more volatile than the S&P 500.
Fennec Pharmaceuticals has higher revenue and earnings than Medicenna Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fennec Pharmaceuticals has a net margin of -2.30% compared to Medicenna Therapeutics' net margin of -533,640.00%. Fennec Pharmaceuticals' return on equity of 29.94% beat Medicenna Therapeutics' return on equity.
14.2% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 1 mentions for Fennec Pharmaceuticals and 0 mentions for Medicenna Therapeutics. Fennec Pharmaceuticals' average media sentiment score of 0.67 beat Medicenna Therapeutics' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Summary
Fennec Pharmaceuticals beats Medicenna Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Medicenna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicenna Therapeutics Competitors List
Related Companies and Tools
This page (TSE:MDNA) was last updated on 9/12/2025 by MarketBeat.com Staff
